Peripheral Arterial Disease Clinical Trial
— VISIONOfficial title:
Evaluation of the Pantheris Optical Coherence Tomography Imaging Atherectomy System for Use in the Peripheral Vasculature
NCT number | NCT01937351 |
Other study ID # | P0555 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 25, 2013 |
Est. completion date | September 20, 2015 |
Verified date | March 2021 |
Source | Avinger, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A non-randomized, prospective, global clinical trial of the Avinger Pantheris System, an atherectomy device that provides directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque in diseased lower extremity arteries.
Status | Completed |
Enrollment | 162 |
Est. completion date | September 20, 2015 |
Est. primary completion date | July 15, 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age = 18 years old; - Subject is a candidate for percutaneous intervention for peripheral arterial disease in the legs; - Subject is willing and able to give informed consent; - Documented symptomatic atherosclerotic peripheral arterial disease Rutherford Classification 2-5; - Reference vessel lumen proximal to target lesion = 2.5 mm and = 7.0 mm in diameter by visual estimation; - Subject has de novo target lesion(s) with stenosis >70% by visual estimation distal to the profunda femoral artery. No more than 2 lesions may be treated with the Pantheris device; - Target lesion length = 15 cm (may be two tandem lesions that do not exceed 15cm in total length); - Subject is capable of meeting requirements and be present at the follow-up clinic visits at 30 days and 6 months; - At least one patent tibial run-off vessel at baseline. Inclusion Criteria for the 24-month follow up: - Completed the 6-month follow-up visit - Re-consented prior to the 24-month follow-up visit Exclusion Criteria: - Subject is pregnant or breast feeding; - Rutherford Class 0 to 1 (asymptomatic and mild claudication); - Rutherford Class 6 (critical limb ischemia); - Moderate to severe calcification of the target lesion; - Acute ischemia and/or acute thrombosis of the Superficial Femoral Artery (SFA)-Popliteal segment; - In-stent restenosis within the target lesion; - Target lesion with any type of stent or graft; - Target lesion in the iliac artery; - Target lesion stenosis <70%; - Subjects with significant (=70%) occlusive lesions proximal to the target lesion not successfully treated during the index procedure (upstream disease) and prior to treatment of the target lesion; - Endovascular or surgical procedure performed on the index limb less than or equal to 30 days prior to the index procedure; - Planned endovascular or surgical procedure 30 days after the index procedure; - Lesion in the contralateral limb requiring intervention during the index procedure or within 30 days of the index procedure; - Subjects with active systemic infections whether they are being currently treated or not; - Subjects on chronic hemodialysis or creatinine level >2.0mg/dL; - Evidence or history of intracranial or gastrointestinal bleeding, intracranial aneurysm, myocardial infarction or stroke within the past 2 months; - Evidence or history of aneurysmal target vessel within the past 2 months; - History of severe trauma, fracture, major surgery or biopsy of a parenchymal organ within the past 14 days; - Known allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately pre-treated; - Subjects in whom anti-platelet, anticoagulant, or thrombolytic therapy is contraindicated; - History of heparin-induced thrombocytopenia (HIT); - Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 100,000/mm2, known coagulopathy, or International Normalized Ratio (INR) >1.5; - Any thrombolytic therapy within 2 weeks of the index procedure; - Any clinical and/or angiographic complication attributed to the use of another device prior to the insertion of the study device into the subject; - Subjects or their legal guardians who have not or will not sign the Informed Consent; - Subjects who are unwilling or unable to comply with the follow-up study requirements; - Participation in any study of an investigational device, medication, biologic or other agent within 30 days prior to enrollment that is either a cardiovascular study or could, in the judgment of the investigator, affect the results of the study. |
Country | Name | City | State |
---|---|---|---|
Germany | Muenster Hospital | Muenster | |
United States | Austin Heart | Austin | Texas |
United States | Deborah Heart and Lung Center | Browns Mills | New Jersey |
United States | Hatton Institute for Research and Education, Good Samaritan Hospital - Bethesda North | Cincinnati | Ohio |
United States | Dayton Heart Center/Good Samaritan Hospital | Dayton | Ohio |
United States | Detroit Medical Center Cardiovascular Institute Harper-Hutzel Hospital | Detroit | Michigan |
United States | St. John Hospital and Medical Center | Detroit | Michigan |
United States | Alexian Brothers Medical Center, Cardiovascular Associates | Elk Grove Village | Illinois |
United States | St. Joseph's Hospital | Fort Wayne | Indiana |
United States | St. Dominic Hospital | Jackson | Mississippi |
United States | St. Bernard's Medical Center | Jonesboro | Arkansas |
United States | Arkansas Heart Hospital | Little Rock | Arkansas |
United States | Methodist Hospital | Memphis | Tennessee |
United States | St. Peters University Hospital | New Brunswick | New Jersey |
United States | Advocate Christ Hospital and Medical Center | Oak Lawn | Illinois |
United States | University of Nebraska Medical Center | Omaha | Nebraska |
United States | Coastal Vascular and Interventional | Pensacola | Florida |
United States | Einstein Medical Center | Philadelphia | Pennsylvania |
United States | Jobst Vascular Center | Toledo | Ohio |
United States | Medstar Washington Hospital | Washington | District of Columbia |
United States | Cedars Sinai Medical Center/Cardiovascular Research Foundation of Southern California | West Hollywood | California |
Lead Sponsor | Collaborator |
---|---|
Avinger, Inc. |
United States, Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary Safety Endpoint | The primary safety endpoint is defined as freedom from a composite of major adverse events (MAE) through 6-Month follow-up as adjudicated by an independent Clinical Events Committee (CEC). Individual MAEs include: Cardiovascular related death Unplanned, major index limb amputation Clinically driven target lesion revascularization (TLR) Myocardial infarction Device related events: Clinically significant perforation Clinically significant dissection Clinically significant embolus Pseudoaneurysm |
Day 0 through 6 Months | |
Primary | Primary Effectiveness Endpoint: Technical Success | The primary efficacy endpoint of technical success is defined as the percent of target lesions that have a residual diameter stenosis <50% post the Pantheris device alone, as assessed by an independent Angiographic Core Laboratory. | Day 0 | |
Secondary | Secondary Safety Endpoint | Freedom from MAEs as defined above, through 30 days (or hospital discharge, whichever is longer) as adjudicated by an independent CEC. | Day 0 through Day 30 | |
Secondary | Secondary Safety Endpoint | Freedom from procedural emboli, defined as a change in any visualized runoff vessel (other than vasospasm and dissection) at any time during the procedure. | Day 0 through 30 days | |
Secondary | Secondary Safety Endpoint | Freedom from clinically driven Target Vessel Revascularization (TVR) through 6 months, as adjudicated by an independent CEC. | Day 0 through 6 Months | |
Secondary | Secondary Effectiveness Endpoint: Procedural Success | Procedural success defined as the percent of target lesions that have residual diameter stenosis < 30% post-Pantheris and any other adjunctive therapy, determined by independent Angiographic Core Laboratory. | Day 0 | |
Secondary | Secondary Effectiveness Endpoint: ABI | Ankle-Brachial Index (ABI) at 30 days. ABI is the ratio of blood pressure in the lower legs to the blood pressure in the arms. ABI between 0.95 and 1.3 is considered normal (free from significant peripheral artery disease). | Day 30 | |
Secondary | Secondary Effectiveness Endpoint: Rutherford Classification | Rutherford Classification at 30 days. Rutherford Classification is a commonly used clinical means for describing the degree of peripheral artery disease. Rutherford Classifications range from Class 0: asymptomatic, to Class 6: major tissue loss. | Day 30 | |
Secondary | Secondary Effectiveness Endpoint: Quality of Life - 12-Item Short Form Survey (SF-12) | Change in Quality of Life measures between Baseline and 30 days using 12-Item Short Form Survey (SF-12). There are two components of the SF-12: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Each yields scores from 0 (representing the worst possible debilitation) to 100 (representing no reduction in quality of life). | Day 30 | |
Secondary | Secondary Effectiveness Endpoint: Vascular Quality of Life Questionnaire (VascuQoL) | Change in Quality of Life measures between Baseline and 30 days using Vascular Quality of Life Questionnaire (VascuQoL). The VascuQoL is a disease-specific questionnaire developed to assess chronic limb ischemia. VascuQol uses a seven-point scale, with 1 representing the worst score and 7 representing the best score. | Day 30 | |
Secondary | Secondary Effectiveness Endpoint: ABI | Ankle-Brachial Index (ABI) at 6 months. ABI is the ratio of blood pressure in the lower legs to the blood pressure in the arms. ABI between 0.95 and 1.3 is considered normal (free from significant peripheral artery disease). | 6 Month | |
Secondary | Secondary Effectiveness Endpoint: Rutherford Classification | Rutherford Classification at 6 months. Rutherford Classification is a commonly used clinical means for describing the degree of peripheral artery disease. Rutherford Classifications range from Class 0: asymptomatic, to Class 6: major tissue loss. | 6 Month | |
Secondary | Secondary Effectiveness Endpoint: Quality of Life - 12-Item Short Form Survey (SF-12) | Change in Quality of Life measures between Baseline and 6 Months using 12-Item Short Form Survey (SF-12). There are two components of the SF-12: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Each yields scores from 0 (representing the worst possible debilitation) to 100 (representing no reduction in quality of life). | 6 Month | |
Secondary | Secondary Effectiveness Endpoint: Vascular Quality of Life Questionnaire (VascuQoL) | Change in Quality of Life measures between Baseline and 6 months using Vascular Quality of Life Questionnaire (VascuQoL). The VascuQoL is a disease-specific questionnaire developed to assess chronic limb ischemia. VascuQol uses a seven-point scale, with 1 representing the worst score and 7 representing the best score. | 6 Month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Active, not recruiting |
NCT03987061 -
MOTIV Bioresorbable Scaffold in BTK Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Active, not recruiting |
NCT04677725 -
NEtwork to Control ATherothrombosis (NEAT Registry)
|
||
Recruiting |
NCT05961943 -
RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients
|
N/A | |
Recruiting |
NCT06047002 -
Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
|
||
Completed |
NCT03185052 -
Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach
|
N/A | |
Recruiting |
NCT05992896 -
A Study of Loco-Regional Liposomal Bupivacaine Injection
|
Phase 4 | |
Completed |
NCT04635501 -
AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial
|
N/A | |
Recruiting |
NCT04584632 -
The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery
|
N/A | |
Withdrawn |
NCT03994185 -
The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease
|
N/A | |
Withdrawn |
NCT03538392 -
Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
|
||
Recruiting |
NCT02915796 -
Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty
|
Phase 1 | |
Active, not recruiting |
NCT02900924 -
Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
|
||
Completed |
NCT02901847 -
To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.
|
N/A | |
Not yet recruiting |
NCT02455726 -
Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
|
N/A | |
Not yet recruiting |
NCT02387450 -
Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication
|
Phase 2/Phase 3 | |
Withdrawn |
NCT02126540 -
Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries
|
N/A | |
Completed |
NCT02384980 -
Saving Life and Limb: FES for the Elderly With PAD
|
Phase 1 |